HTG Molecular Diagnostics Receives European Patent Grant Notification for Methods for Subtyping Diffuse Large B-cell Lymphoma
(WorldNews Health)

TUCSON, Ariz., Jan. 28, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received notification of validation of European patent number EP 3356554 for its methods for subtyping diffuse large B-cell lymphoma (DLBCL), effective October 2019. HTG was previously granted a patent for this technology in the United States in 2018. Lymphoma is the most common blood cancer, and DLBCL is the most common form of non-Hodgkin`s lymphoma, accounting for up to 30 percent...